Jaydutt Vadgama to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Jaydutt Vadgama has written about Drug Resistance, Neoplasm.
Connection Strength
1.120
-
Li Y, Wu Y, Abbatiello TC, Wu WL, Kim JR, Sarkissyan M, Sarkissyan S, Chung SS, Elshimali Y, Vadgama JV. Slug contributes to cancer progression by direct regulation of ERa signaling pathway. Int J Oncol. 2015 Apr; 46(4):1461-72.
Score: 0.454
-
Nava M, Dutta P, Farias-Eisner R, Vadgama JV, Wu Y. Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance. Sci Rep. 2019 03 26; 9(1):5141.
Score: 0.151
-
Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, Farias-Eisner R, Vadgama JV. A83-01 inhibits TGF-?-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017 Jun; 163(3):449-460.
Score: 0.131
-
Chung SS, Oliva B, Dwabe S, Vadgama JV. Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase. Int J Oncol. 2016 Aug; 49(2):487-98.
Score: 0.124
-
Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014 Feb; 44(2):403-11.
Score: 0.104
-
Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Expression of Wnt3 activates Wnt/?-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012 Dec; 10(12):1597-606.
Score: 0.097
-
Nava M, Dutta P, Zemke NR, Farias-Eisner R, Vadgama JV, Wu Y. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets. BMC Med Genomics. 2019 02 08; 12(1):32.
Score: 0.037
-
Yin D, Chen W, O'Kelly J, Lu D, Ham M, Doan NB, Xie D, Wang C, Vadgama J, Said JW, Black KL, Koeffler HP. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer. 2010 Nov 15; 127(10):2257-67.
Score: 0.021